- MetAlert recently announced the signing of an LOI with Sensio Group for the marketing and distribution of RoomMate, a 3D Infrared supervision product with a fall detection automated monitoring system
- The company has set out to solve problems unique to individuals afflicted with ADA by creating devices specific to their use cases, and RoomMate is one such product, promising effective remote patient monitoring while maintaining anonymity
- Through this partnership, MetAlert looks to penetrate the high CAGR projected patient monitoring devices market, valued at $47 billion in 2021
- It also looks to leverage the partnership for future up-listing onto a major exchange such as NASDAQ
- Its management is confident that with its value proposition and unique market positioning, it will soon position MetAlert as a dominant player in its sector, commanding a significant market share and realizing substantial earnings
MetAlert (OTC: MLRT), a Los Angeles-based pioneer in location-sensitive health monitoring devices and wearable technology products, announced the signing of a Letter of Intent (“LOI”) with Sensio Group, a Norway-based provider of welfare technology and home automation solutions, for the marketing and distribution of RoomMate(TM). MetAlert hopes this partnership will initiate the promotion of this new product in the U.S., Canada, and the U.K., leveraging on Sensio’s understanding of the existing market, its brand equity, and its robust distribution network.
“We are very excited about this partnership and remarkable proven technology. With over 5,500 RoomMates in operation in 220 municipalities across Norway, Sweden, Denmark, and Iceland, we will begin marketing and distributing the product and monitoring service in the U.S., Canada, and the…
NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
